Overview

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of poly (ADP-Ribose) polymerase inhibitor E7016 when used with temozolomide (TMZ) in patients with advanced solid tumors and gliomas.

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Inc.

Treatments:

10-((4-hydroxypiperidin-1-yl)methyl)chromeno(4,3,2-de)phthalazin-3(2H)-one
Poly(ADP-ribose) Polymerase Inhibitors
Temozolomide